Search
Molecular Partners AG
MOLNAdd to Watchlist
4.210USD
0.0000.00%
Close 08-14 16:00（ET）Quotes delayed by 15 min
167.34MMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-14The current earnings forecast score of Molecular Partners AG is 8.00, ranking 170 out of 387 in the Biotechnology & Medical Research industry. The average price target is 13.62, with a high of 17.00 and a low of 10.00.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
13.000
Target Price
+208.79%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Molecular Partners AG
MOLN
5
Beigene Ltd
ONC
28
argenx SE
ARGX
28
Ionis Pharmaceuticals Inc
IONS
25
IQVIA Holdings Inc
IQV
24
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Molecular Partners AG's price target?
Analysts forecast that Molecular Partners AG's price target is USD 13.62, with the highest forecast at USD 17.00 and the lowest forecast at USD 10.00.
How have Molecular Partners AGMOLN's recent earnings per share performed?
The market expectation was USD -0.44, while Molecular Partners AGMOLN's earnings per share (EPS) for the previous quarter was USD -0.42. EPS for the next quarter is expected at USD -0.43.
What is the analyst rating for Molecular Partners AG?
Based on the ratings of Molecular Partners AG's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.